Eco-Stim Energy Solutions Completes Equity Private

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Eco-Stim Energy Solutions Completes Equity Private Placement

HOUSTON, July 9, 2014 (GLOBE NEWSWIRE) -- Eco-Stim Energy Solutions, Inc. ("EcoStim" or "the Company") (OTCQB:ESES) today announced that Albright Capital Management, LLC ("ACM"), an emerging markets investment firm headquartered in Washington, DC exercised its option to purchase 1,333,333 shares of the Company's common stock at $6 per share for net proceeds of approximately $8 million, pursuant to the previously announced securities purchase option agreement, dated May 29, 2014 (the "Option Agreement"). This option was granted to ACM in connection with the $22 million convertible debt facility the Company closed with ACM in May 2014. The Company has borrowed $11.8 million under the convertible debt facility. In connection with the consummation of the exercise of the option, ACM will have the ability to appoint two additional members to the EcoStim board of directors. The Company intends to use the net proceeds of approximately $30 million from the exercise of ACM's option and the convertible note facility for working capital and capital expenditures related to additional well stimulation and coiled tubing assets to be utilized in the rapidly growing Argentina oilfield service market. In accordance with the Option Agreement, the closing of the option exercise is expected to occur within three days and is subject to customary closing conditions.

J. Chris Boswell, EcoStim's President and Chief Executive Officer, stated, "We are excited that ACM has elected to exercise their equity option. We feel this equity participation better aligns their overall interest with those of the management team and other shareholders. Their involvement brings valuable experience to our board as we continue to grow our Company in emerging markets around the world. We believe that ACM shares the vision for our Company and has the unique skill sets to complement our management team. This commitment to our Company not only makes us stronger financially, but also strategically. We believe that with 80% of the world's shale resources located outside of North America and roughly 80% of the required equipment, know-how and technology located in North America, that our services will be well received in the markets we are pursuing. International business experience and relationships matter and having ACM's expertise and influence internationally will give us an additional competitive advantage."

About the Company

Eco-Stim Energy Solutions is an environmentally focused oilfield service and technology company providing proprietary field management technologies and well stimulation and completion services to oil and gas producers drilling in the rapidly expanding international unconventional shale market. EcoStim's proprietary methodology and technology offers the potential to decrease the number of stages stimulated in shale plays through a unique process that predicts high probability production zones while confirming those production zones using the latest generation down-hole diagnostic tools. In addition, EcoStim offers its clients completion techniques that can dramatically reduce horsepower requirements, emissions, surface footprint and water usage. EcoStim seeks to deliver well completion services with better technology, better ecology and significantly improved economics for unconventional oil and gas producers worldwide.

Forward-Looking Statements:

The foregoing contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made by the Company based on management's experience, expectations and perception of historical trends, current conditions, anticipated future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of performance. Although the Company believes the expectations reflected in Its forward-looking statements are reasonable and are based on reasonable assumptions, no assurance can be given that these assumptions are accurate or that any of these expectations will be achieved (in full or at all) or will prove to have been correct. Moreover, such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. These Include the factors discussed or referenced in the "Risk Factors" section of the Company's 10-K filed with the Securities and Exchange Commission on March 28, 2014 and risks relating to expected continued development of fracturing operations and unconventional activity in Argentina ; expected financial results for past and future periods; the effects of government regulation ; permitting and other legal requirements, including new legislation or regulation of hydraulic fracturing; drilling and operating risks; the adequacy of the Company's resources and liquidity; difficult and adverse conditions in the domestic and global capital and credit markets; risks related to the concentration of our operations in South America; shortages of oilfield and well stimulation service equipment, services and qualified personnel and increases in costs for such equipment, services and personnel; uncertainties about the Company's ability to successfully execute its business and financial plans and strategies; general economic and business conditions, either internationally or domestically or in the jurisdictions in which the Company operates; competition in the oil and natural gas industry; uncertainty concerning the Company's assumed or possible future results of operations; the Company's existing indebtedness; and other important factors that could cause actual results to differ materially from those projected.

Any forward-looking statement speaks only as of the date on which such statement is made and the Company undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.

Alexander Nickolatos, CFO 281-531-7200

Scroll down for more posts ▼

Top 10 Most Recent News Articles

KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 9

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 123

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 52

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 422

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 175

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 104

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 0

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 432

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 287

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 557

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading

Top 5 Most Recently Viewed Articles

NKGen Biotech to Present Innovative Research at Global Congress

Updated Category News Views 157

NKGen Biotech's Exciting Announcement on Upcoming Presentation NKGen Biotech Inc. (NASDAQ: NKGN), a pioneering clinical-stage biotechnology firm dedicated to developing cutting-edge autologous and allogeneic natural killer cell therapies, has recently shared some thrilling news regarding their participation in an international event. Highlighting Neurodegenerative...

Continue Reading
Celebrating Case Managers: A Call to Action for 2025

Updated Category News Views 522

Recognizing the Contribution of Case Managers in 2025 Case managers have proven time and again to be essential contributors to the health and human services spectrum. In 2025, the two prominent organizations in the case management field—the American Case Management Association (ACMA) and the Commission for Case Manager Certification (CCMC)—have once again partnered to...

Continue Reading
Faruqi & Faruqi Investigates Ford Investor Claims

Updated Category News Views 92

Back in 2024, Faruqi & Faruqi took aim at Ford Motor Company (NYSE: F), investigating claims from investors who’d racked up losses over $100,000. They were diving deep into the financial mess at Ford—a colossal vehicle manufacturer that found itself knee-deep in allegations of breaching federal securities laws. The chatter was all about how quality assurance failures...

Continue Reading
Entourage Health Announces Going-Private Arrangement Plan

Updated Category News Views 236

Entourage Health Corp. Takes a Bold Step Toward Going-Private Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) has officially entered into a significant arrangement agreement with 1001007762 Ontario Inc. and 2437653 Ontario Inc. This strategic move, a statutory plan under the Business Corporations Act (Ontario), sees the Purchaser agreeing to acquire all common shares...

Continue Reading
A&W Revenue Royalties Income Fund Q3 2024 Results Review

Updated Category News Views 183

A&W Revenue Royalties Income Fund Q3 2024 Financial Overview TRADING SYMBOL: TSX: AW.UN A&W Revenue Royalties Income Fund has reported encouraging results for the third quarter ending this year. The quarterly performance reflects steady royalty income growth and strategic developments that promise an exciting future. Royalty Income Performance In the third quarter of...

Continue Reading